Treatment with once-daily exenatide plus dapagliflozin and without rescue therapy was associated with clinically relevant changes in fasting plasma glucose.
This report provides an update on the use of diagnostic tests for asymptomatic primary hyperparathyroidism in clinical practice.
Integrated, pooled efficacy data from the phase 2 and phase 3 OPTIC trials of teprotumumab (Horizon Therapeutics) found that the treatment led to significant reductions in inflammation, proptosis (eye bulging) and diplopia (double vision) in patients with active thyroid eye disease (TED).
Investigators examined the safety and efficacy of metreleptin in patients with congenital or acquired generalized lipodystrophy.
Overall, once-weekly semaglutide 1.0 mg as an add-on to basal insulin is the most efficacious GLP-1 receptor agonist in terms of reductions in HbA1c and body weight from baseline after 6 months of treatment.
Patients initiating DPP-4 inhibitors as third-line therapy in type 2 diabetes appeared to have lower discontinuation rates and less hypoglycemia compared with patients starting NPH insulin.
Study compared the real-world effectiveness of canagliflozin 300 mg vs dapagliflozin 10 mg on HbA1c reduction in patients with type 2 diabetes.
Compared to standard insulin treatment, noninsulin antidiabetic agents did not present an increased risk for fetal losses or major malformations when used in the first trimester of pregnancy.
Crysvita is an antibody that blocks fibroblast growth factor 23 (FGF23), a hormone that causes phosphate urinary excretion and suppresses active vitamin D production by the kidney.
Investigators assessed the association between the cumulative dose of oral glucocorticoid treatment and expense associated with adverse events in patients with rheumatoid arthritis.
